Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Retained Earnings (2023 - 2025)

Historic Retained Earnings for Connect Biopharma Holdings (CNTB) over the last 3 years, with Q3 2025 value amounting to -$385.7 million.

  • Connect Biopharma Holdings' Retained Earnings changed N/A to -$385.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$385.7 million, marking a year-over-year change of. This contributed to the annual value of -$345.4 million for FY2024, which is 473.97% down from last year.
  • Per Connect Biopharma Holdings' latest filing, its Retained Earnings stood at -$385.7 million for Q3 2025.
  • Connect Biopharma Holdings' Retained Earnings' 5-year high stood at -$329.7 million during Q4 2023, with a 5-year trough of -$531.7 million in Q2 2024.
  • Moreover, its 3-year median value for Retained Earnings was -$368.5 million (2025), whereas its average is -$397.9 million.
  • As far as peak fluctuations go, Connect Biopharma Holdings' Retained Earnings plummeted by 1342.6% in 2024, and later skyrocketed by 3068.88% in 2025.
  • Connect Biopharma Holdings' Retained Earnings (Quarter) stood at -$329.7 million in 2023, then dropped by 4.74% to -$345.4 million in 2024, then decreased by 11.69% to -$385.7 million in 2025.
  • Its Retained Earnings was -$385.7 million in Q3 2025, compared to -$368.5 million in Q2 2025 and -$355.6 million in Q1 2025.